Genolution

Genolution EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Genolution (225220.KQ) as of Oct 22, 2026 is -4.39. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.73 — a change of 153.55% (lower).

EV/FCF

-4.39

YoY

153.55%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Genolution is 2025 -4.39 . EV/FCF (Enterprise Value to Free Cash Flow) of Genolution was 2024 -1.73 . It decreases by 153.55% lower compared to the previous year.

The Genolution EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-10.49 KRW
Jan 1, 2019
-10.06 KRW
Jan 1, 2020
-0.26 KRW
Jan 1, 2021
-0.64 KRW
Jan 1, 2022
-0.15 KRW
Jan 1, 2023
-1.75 KRW
Jan 1, 2024
-1.73 KRW
Jan 1, 2025
-4.39 KRW
The Genolution EV/FCF history
YEAREV/FCFYoY
-4.39+153.55%
-1.73-1.03%
-1.75+1,039.19%
-0.15-76.11%
-0.64+149.30%
-0.26-97.44%
-10.06-4.15%
-10.49-95.04%
-211.40+166.77%
-79.25—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

EV/FCF (Enterprise Value to Free Cash Flow) of Genolution is -4.39 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Genolution changed from -1.73 to -4.39, representing a 153.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Genolution since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genolution

All Key Metrics — Genolution